» Articles » PMID: 19507254

Mutations of NFKBIA, Encoding IkappaB Alpha, Are a Recurrent Finding in Classical Hodgkin Lymphoma but Are Not a Unifying Feature of Non-EBV-associated Cases

Overview
Journal Int J Cancer
Specialty Oncology
Date 2009 Jun 10
PMID 19507254
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

A consistent feature of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) is the constitutive activation of NF-kappaB transcription factors. In Epstein-Barr virus (EBV)-associated cases of cHL, expression of viral antigens most probably leads to NF-kappaB activation but for non-EBV-associated cases, the mechanism is not clear. Previous small studies have demonstrated deleterious mutations of NFKBIA, the gene encoding IkappaB alpha, in HRS cells. In the present study, we aimed to establish the frequency of NFKBIA mutation in cHL by investigating a larger series of cases and to determine whether these mutations are a characteristic feature of non-EBV-associated cHL. Single HRS cells from 20 cases of cHL were analysed by PCRs covering all 6 exons of the gene. Clonal deleterious mutations were detected in 3 cases and in 1 case both alleles of the gene were shown to harbour mutations. NFKBIA mutations were detected only in non-EBV-associated cases but the majority of these cases had wild-type NFKBIA. It remains possible that defects in genes encoding other inhibitors of NF-kappaB, such as TNFAIP3 (A20) and CYLD, are involved in the latter cases, as described for one case in this series.

Citing Articles

A Review on Picrosides Targeting NFκB and its Proteins for Treatment of Breast Cancer.

Soni D, Anjum Z, Raza K, Verma S Cell Biochem Biophys. 2024; 82(2):575-591.

PMID: 38724755 DOI: 10.1007/s12013-024-01281-1.


Identification and Interpretation of eQTL and eGenes for Hodgkin Lymphoma Susceptibility.

An Y, Lee C Genes (Basel). 2023; 14(6).

PMID: 37372322 PMC: 10298295. DOI: 10.3390/genes14061142.


[Classification of Hodgkin lymphoma and related entities : News and open questions].

Hartmann S, Fend F Pathologie (Heidelb). 2023; 44(3):184-192.

PMID: 36930284 DOI: 10.1007/s00292-023-01188-3.


EBV-associated diseases: Current therapeutics and emerging technologies.

Chakravorty S, Afzali B, Kazemian M Front Immunol. 2022; 13:1059133.

PMID: 36389670 PMC: 9647127. DOI: 10.3389/fimmu.2022.1059133.


Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma.

van Bladel D, Stevens W, Brand M, Kroeze L, Groenen P, van Krieken J Cancers (Basel). 2022; 14(13).

PMID: 35805000 PMC: 9264882. DOI: 10.3390/cancers14133222.